Cancer Immunology, Immunotherapy

, Volume 56, Issue 6, pp 753–759

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

  • Danièle Godelaine
  • Javier Carrasco
  • Francis Brasseur
  • Bart Neyns
  • Kris Thielemans
  • Thierry Boon
  • Aline Van Pel
Original Article

Abstract

A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.

Keywords

Antigenic peptide Cancer immunotherapy Cytolytic T lymphocytes MAGE Melanoma 

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Danièle Godelaine
    • 1
    • 2
  • Javier Carrasco
    • 1
    • 2
  • Francis Brasseur
    • 1
    • 2
  • Bart Neyns
    • 3
  • Kris Thielemans
    • 4
  • Thierry Boon
    • 1
    • 2
  • Aline Van Pel
    • 1
    • 2
  1. 1.Ludwig Institute for Cancer ResearchBrusselsBelgium
  2. 2.Institute of Cellular Pathology, Cellular Genetics UnitUniversité Catholique de LouvainBrusselsBelgium
  3. 3.Department of Medical OncologyOncology CenterBrusselsBelgium
  4. 4.Laboratory of PhysiologyVrije Universiteit Brussel Faculty of MedicineBrusselsBelgium

Personalised recommendations